When do biologic drug patents expire and when will biosimilars launch?

US Patent 8,268,303: Critical Claims & U.S. Patent Landscape for hESC-Derived RPE (Pax6-/Bestrophin+/CRALBP+/PEDF+/RPE65+)

Executive summary: U.S. Patent 8,268,303 claims methods for differentiating human embryonic stem (hES) cells into human retinal pigment epithelium (RPE) cells characterized by Pax6−, bestrophin+, CRALBP+, PEDF+, and RPE65 expression, and related administration/transplantation methods (notably for retinal diseases and Parkinson’s disease). The claim structure is built around three enforceability pillars: (1) an RPE differentiation workflow (multilayer overgrowth on MEF or embryoid body formation, pigment appearance timing, and pigmented cell isolation); (2) functional/phenotypic cell identity constraints (marker and “brown pigment in cytoplasm” descriptors); and (3) downstream use and delivery settings (subretinal transplantation by vitrectomy; cell suspension/matrix/substrate). Competitive risk is driven by whether other players’ processes avoid the claimed combination of culture geometry (multilayer/EB), feeder/medium conditions, differentiation duration bands, and the exact marker panel or reframe around alternative starting cell types (e.g., iPSC), delivery, or manufacturing endpoints.

What is US 8,268,303 claiming for hES-to-RPE differentiation and cell identity?

Core claim scope: the “Pax6−/bestrophin+/CRALBP+/PEDF+/RPE65+” RPE endpoint

Claims 1, 16, 28 (and dependent variants) are directed to methods for differentiation of hES cells into RPE cells where the resulting cells meet a specific identity definition:

Negative marker: Pax6−
Positive markers: bestrophin+, CRALBP+, PEDF+, and express RPE65
Morphology and pigment descriptor: pigmented cells containing “brown pigment dispersed in their cytoplasm”; in some dependents “cobblestone, polygonal appearance characteristic of epithelial cells.”

Patent-enforcement implication: Even if an accused process follows a broadly similar differentiation timeline, infringement analysis will focus on whether the resulting cells are demonstrably within the claimed marker/phenotype set. This creates both (a) a defensible moat for plaintiffs when their cells can be shown to match the marker panel and (b) a design-around pathway for competitors if they can demonstrate marker divergence (or use different identity metrics).

Two alternative process routes within the same concept

The independent claims provide two major manufacturing “routes”:

Route A (multilayer overgrowth): hES cultures overgrow on MEF to form a thick multilayer or alternatively overgrow on feeder-free equivalents in related dependent claim sets.
Route B (embryoid body): form an embryoid body (EB) and culture until pigmented cells appear.

Both routes converge on the same endpoint: isolation and culture of pigmented cells to obtain the defined RPE population.

Pigmented-cell induction requirement

All differentiation claims require culturing for a sufficient time for appearance of pigmented cells with brown cytoplasmic pigment. Dependent claims harden timing into bands:

At least 6 weeks (claims 5, 20, 33)
Between ~6 and 8 weeks (claims 6, 21, 34)
Between ~3 and 5 months (claims 7, 22, 35)

Enforceability implication: Competitors using substantially faster or slower protocols may aim to avoid specific timing dependents, but the independent “sufficient time” language remains a wide hook.

Isolation step as a narrower dependent constraint

Claim 2 / 17 / 29 narrow the isolation to enzyme contact with one or more of:

trypsin
collagenase
dispase

This sets up a common infringement defense pattern in cell manufacturing: using mechanical dissociation, different enzymes, or purification methods not falling within the claimed set.

Medium condition carve-outs as additional defense targets

Claim 4 / 19 / 31 require culturing in a medium lacking:

exogenously added FGF
exogenously added LIF
exogenously added PLASMANATE™

Claim 32 adds: EB cultured in absence of feeder cells.

Design-around implication: “Lacking exogenously added” is narrower than “absence of all signaling”; competitors can argue for baseline endogenous/trace factors, or different additive regimes. For infringement, the key is what is actually used in the manufacturing medium.

Which U.S. uses are covered: retinal transplantation and Parkinson’s disease?

Administration claims (RPE cell administration with the same identity endpoint)

Claims 8, 23, 38 define administration methods using the same manufacturing-to-RPE identity backbone. They include:

allowing hES cultures to overgrow on MEF and form thick multilayers or forming EB
culturing until pigmented cells appear
isolating and culturing pigmented cells to obtain RPE with the marker panel
introducing the human RPE cells into an individual

Dependent claims specify disease and route.

Retinitis pigmentosa and/or macular degeneration

Claim 9 / 24: individual suffers from retinitis pigmentosa and/or macular degeneration.

Claim 10 / 25: transplantation by vitrectomy surgery into the subretinal space.

Claim 11 / 26: cells transplanted in suspension, matrix, or substrate.

Enforceability implication: If a competitor treats different retinal indications, uses a different surgical route (e.g., intravitreal rather than subretinal), or avoids vitrectomy subretinal delivery, it may avoid these dependents. But the independent administration claims remain broad for “introducing” cells into “an individual in need thereof” if coupled to the same RPE manufacturing identity.

Animal model evaluation of outcomes

Claims 12–14 add explicit model lists and evaluation endpoints. These are most relevant to enforcement against research-to-development activity, not late-stage commercial delivery, unless investigators proceed under instructions tied to the claims.

Parkinson’s disease indication

Claims 15 / 27 are directed to treatment of Parkinson’s disease via the same hES-to-RPE differentiation and introduction steps.

Commercial/legal implication: Parkinson’s programs often aim to justify rationale via neurotrophic support, retinal cell integration, or retinal-like trophic functions. If the clinical strategy uses RPE as the therapeutic cell type made by the claimed method, the Parkinson’s dependent use is a direct enforcement lever.

What is the patent’s “most litigable” claim set: phenotype endpoint, timing, or route (MEF multilayer vs EB)?

Most central: the phenotype endpoint

All independent claims require the same core RPE identity constraints. This typically becomes the focal point in any infringement fight:

What markers are actually expressed in the manufactured RPE?
What assay methods confirm “bestrophin+, CRALBP+, PEDF+, express RPE65” and Pax6−?

Practical risk mapping: If a competitor’s product is characterized as “RPE-like” but not shown to meet the exact panel in a validated manner, they may reduce infringement risk. Conversely, if they can demonstrate the panel, they may accept the risk that “RPE identity” is met.

Second focal: the differentiation workflow inputs

The patent offers multiple independent routes (MEF-thick multilayer and EB). That reduces the effectiveness of a simple switch from one differentiation format to another.

Instead, competitors likely pivot to:

different starting cells (iPSC instead of hES),
different differentiation logic (e.g., direct differentiation protocols without thick multilayer/EB as defined),
and/or different endpoints (different maturation marker sets).

Timing bands matter mainly for dependents

Dependents specify durations in discrete windows. If a competitor can argue their process is outside those bands, the dependent claims may not be in play. However, the independent “sufficient time” remains.

How do the dependent claims create a layered design-around strategy?

Isolation-by-enzyme (trypsin/collagenase/dispase)

If a competitor uses:

EDTA-based dissociation,
accutase,
mechanical harvesting,
alternative proteases, then it may avoid dependent claims 2/17/29.

But the independent claims do not require that enzyme set. So avoiding this dependent constraint does not eliminate risk unless the court also finds that the accused process does not meet the independent elements (including the endpoint identity).

Medium additive exclusions (FGF, LIF, PLASMANATE™)

If a competitor uses media that includes any of:

exogenous FGF
exogenous LIF
exogenous PLASMANATE™ they can argue they avoid dependent claims 4/19/31.

Again, the independent differentiation claims do not require these exclusions, so the medium carve-out mainly controls dependent infringement strength.

Feeder-free EB

Claim 32 requires EB in absence of feeder cells. Competitors using feeder-supported EB models may avoid that dependent.

Duration bands

Claims 5–7, 20–22, 33–35 create discrete time windows. Competitors can mitigate risk by moving outside these windows or showing that their “pigmented cell appearance” does not fall within claimed bands.

What is the Orange Book status of US 8,268,303, and where would it likely show up?

No response.

Which companies are likely exposed to US 8,268,303 for hES-derived RPE and RPE cell therapy manufacturing?

No response.

What generic or biosimilar risk exists for this patent in U.S. cell therapy markets?

No response.

How strong is the patent estate around differentiation-to-RPE phenotype claims like this?

No response.

How does US 8,268,303 compare with adjacent RPE differentiation method patents (MEF multilayer vs EB)?

No response.

What patent-litigation events could impact enforceability or claim construction?

No response.

Key Takeaways

US 8,268,303 is centered on an hES-to-RPE manufacturing endpoint defined by a specific marker and function phenotype: Pax6−, bestrophin+, CRALBP+, PEDF+, and RPE65+ plus pigmented cytoplasm descriptor.
It covers two differentiation process formats in independent claims: thick multilayer overgrowth (on MEF in one formulation) and embryoid body (EB), both converging on pigmented cell induction and isolation.
The patent’s most enforceable elements are likely the endpoint identity constraints and the core workflow elements leading to brown cytoplasmic pigment and pigmented-cell isolation.
Dependent claims add narrower constraints on:
- enzyme used for isolation (trypsin/collagenase/dispase),
- media additive absence (no exogenous FGF/LIF/PLASMANATE™),
- duration bands (6–8 weeks and 3–5 months),
- and specific administration settings (vitrectomy subretinal delivery; suspension/matrix/substrate).
Competitor design-around is most plausible via process endpoint divergence (marker panel mismatch) or starting cell type change, with timing and enzyme/media/route constraints used to defeat dependent layers.

FAQs

Does the patent require Pax6 to be absent by a specific assay method?
Are “brown pigment dispersed in cytoplasm” and bestrophin/CRALBP co-validated as an inseparable identity package?
If a program uses iPSC-derived RPE instead of hES, does infringement risk persist under the same claim language?
How do alternative routes of ocular delivery (intravitreal vs subretinal) map to dependent claim coverage?
What manufacturing recordkeeping would most directly establish or refute the marker-panel endpoint in litigation?

References (APA)

No response.

Title:	Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
Abstract:	This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Inventor(s):	Klimanskaya; Irina V. (Upton, MA), Lanza; Robert P. (Clinton, MA)
Assignee:	Advanced Cell Technology, Inc. (Marlborough, MA)
Application Number:	12/857,911
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 8,268,303: Critical Claims & U.S. Patent Landscape for hESC-Derived RPE (Pax6-/Bestrophin+/CRALBP+/PEDF+/RPE65+) Executive summary: U.S. Patent 8,268,303 claims methods for differentiating human embryonic stem (hES) cells into human retinal pigment epithelium (RPE) cells characterized by Pax6−, bestrophin+, CRALBP+, PEDF+, and RPE65 expression, and related administration/transplantation methods (notably for retinal diseases and Parkinson’s disease). The claim structure is built around three enforceability pillars: (1) an RPE differentiation workflow (multilayer overgrowth on MEF or embryoid body formation, pigment appearance timing, and pigmented cell isolation); (2) functional/phenotypic cell identity constraints (marker and “brown pigment in cytoplasm” descriptors); and (3) downstream use and delivery settings (subretinal transplantation by vitrectomy; cell suspension/matrix/substrate). Competitive risk is driven by whether other players’ processes avoid the claimed combination of culture geometry (multilayer/EB), feeder/medium conditions, differentiation duration bands, and the exact marker panel or reframe around alternative starting cell types (e.g., iPSC), delivery, or manufacturing endpoints. What is US 8,268,303 claiming for hES-to-RPE differentiation and cell identity? Core claim scope: the “Pax6−/bestrophin+/CRALBP+/PEDF+/RPE65+” RPE endpoint Claims 1, 16, 28 (and dependent variants) are directed to methods for differentiation of hES cells into RPE cells where the resulting cells meet a specific identity definition: Negative marker: Pax6− Positive markers: bestrophin+, CRALBP+, PEDF+, and express RPE65 Morphology and pigment descriptor: pigmented cells containing “brown pigment dispersed in their cytoplasm”; in some dependents “cobblestone, polygonal appearance characteristic of epithelial cells.” Patent-enforcement implication: Even if an accused process follows a broadly similar differentiation timeline, infringement analysis will focus on whether the resulting cells are demonstrably within the claimed marker/phenotype set. This creates both (a) a defensible moat for plaintiffs when their cells can be shown to match the marker panel and (b) a design-around pathway for competitors if they can demonstrate marker divergence (or use different identity metrics). Two alternative process routes within the same concept The independent claims provide two major manufacturing “routes”: Route A (multilayer overgrowth): hES cultures overgrow on MEF to form a thick multilayer or alternatively overgrow on feeder-free equivalents in related dependent claim sets. Route B (embryoid body): form an embryoid body (EB) and culture until pigmented cells appear. Both routes converge on the same endpoint: isolation and culture of pigmented cells to obtain the defined RPE population. Pigmented-cell induction requirement All differentiation claims require culturing for a sufficient time for appearance of pigmented cells with brown cytoplasmic pigment. Dependent claims harden timing into bands: At least 6 weeks (claims 5, 20, 33) Between ~6 and 8 weeks (claims 6, 21, 34) Between ~3 and 5 months (claims 7, 22, 35) Enforceability implication: Competitors using substantially faster or slower protocols may aim to avoid specific timing dependents, but the independent “sufficient time” language remains a wide hook. Isolation step as a narrower dependent constraint Claim 2 / 17 / 29 narrow the isolation to enzyme contact with one or more of: trypsin collagenase dispase This sets up a common infringement defense pattern in cell manufacturing: using mechanical dissociation, different enzymes, or purification methods not falling within the claimed set. Medium condition carve-outs as additional defense targets Claim 4 / 19 / 31 require culturing in a medium lacking: exogenously added FGF exogenously added LIF exogenously added PLASMANATE™ Claim 32 adds: EB cultured in absence of feeder cells. Design-around implication: “Lacking exogenously added” is narrower than “absence of all signaling”; competitors can argue for baseline endogenous/trace factors, or different additive regimes. For infringement, the key is what is actually used in the manufacturing medium. Which U.S. uses are covered: retinal transplantation and Parkinson’s disease? Administration claims (RPE cell administration with the same identity endpoint) Claims 8, 23, 38 define administration methods using the same manufacturing-to-RPE identity backbone. They include: allowing hES cultures to overgrow on MEF and form thick multilayers or forming EB culturing until pigmented cells appear isolating and culturing pigmented cells to obtain RPE with the marker panel introducing the human RPE cells into an individual Dependent claims specify disease and route. Retinitis pigmentosa and/or macular degeneration Claim 9 / 24: individual suffers from retinitis pigmentosa and/or macular degeneration. Claim 10 / 25: transplantation by vitrectomy surgery into the subretinal space. Claim 11 / 26: cells transplanted in suspension, matrix, or substrate. Enforceability implication: If a competitor treats different retinal indications, uses a different surgical route (e.g., intravitreal rather than subretinal), or avoids vitrectomy subretinal delivery, it may avoid these dependents. But the independent administration claims remain broad for “introducing” cells into “an individual in need thereof” if coupled to the same RPE manufacturing identity. Animal model evaluation of outcomes Claims 12–14 add explicit model lists and evaluation endpoints. These are most relevant to enforcement against research-to-development activity, not late-stage commercial delivery, unless investigators proceed under instructions tied to the claims. Parkinson’s disease indication Claims 15 / 27 are directed to treatment of Parkinson’s disease via the same hES-to-RPE differentiation and introduction steps. Commercial/legal implication: Parkinson’s programs often aim to justify rationale via neurotrophic support, retinal cell integration, or retinal-like trophic functions. If the clinical strategy uses RPE as the therapeutic cell type made by the claimed method, the Parkinson’s dependent use is a direct enforcement lever. What is the patent’s “most litigable” claim set: phenotype endpoint, timing, or route (MEF multilayer vs EB)? Most central: the phenotype endpoint All independent claims require the same core RPE identity constraints. This typically becomes the focal point in any infringement fight: What markers are actually expressed in the manufactured RPE? What assay methods confirm “bestrophin+, CRALBP+, PEDF+, express RPE65” and Pax6−? Practical risk mapping: If a competitor’s product is characterized as “RPE-like” but not shown to meet the exact panel in a validated manner, they may reduce infringement risk. Conversely, if they can demonstrate the panel, they may accept the risk that “RPE identity” is met. Second focal: the differentiation workflow inputs The patent offers multiple independent routes (MEF-thick multilayer and EB). That reduces the effectiveness of a simple switch from one differentiation format to another. Instead, competitors likely pivot to: different starting cells (iPSC instead of hES), different differentiation logic (e.g., direct differentiation protocols without thick multilayer/EB as defined), and/or different endpoints (different maturation marker sets). Timing bands matter mainly for dependents Dependents specify durations in discrete windows. If a competitor can argue their process is outside those bands, the dependent claims may not be in play. However, the independent “sufficient time” remains. How do the dependent claims create a layered design-around strategy? Isolation-by-enzyme (trypsin/collagenase/dispase) If a competitor uses: EDTA-based dissociation, accutase, mechanical harvesting, alternative proteases, then it may avoid dependent claims 2/17/29. But the independent claims do not require that enzyme set. So avoiding this dependent constraint does not eliminate risk unless the court also finds that the accused process does not meet the independent elements (including the endpoint identity). Medium additive exclusions (FGF, LIF, PLASMANATE™) If a competitor uses media that includes any of: exogenous FGF exogenous LIF exogenous PLASMANATE™ they can argue they avoid dependent claims 4/19/31. Again, the independent differentiation claims do not require these exclusions, so the medium carve-out mainly controls dependent infringement strength. Feeder-free EB Claim 32 requires EB in absence of feeder cells. Competitors using feeder-supported EB models may avoid that dependent. Duration bands Claims 5–7, 20–22, 33–35 create discrete time windows. Competitors can mitigate risk by moving outside these windows or showing that their “pigmented cell appearance” does not fall within claimed bands. What is the Orange Book status of US 8,268,303, and where would it likely show up? No response. Which companies are likely exposed to US 8,268,303 for hES-derived RPE and RPE cell therapy manufacturing? No response. What generic or biosimilar risk exists for this patent in U.S. cell therapy markets? No response. How strong is the patent estate around differentiation-to-RPE phenotype claims like this? No response. How does US 8,268,303 compare with adjacent RPE differentiation method patents (MEF multilayer vs EB)? No response. What patent-litigation events could impact enforceability or claim construction? No response. Key Takeaways US 8,268,303 is centered on an hES-to-RPE manufacturing endpoint defined by a specific marker and function phenotype: Pax6−, bestrophin+, CRALBP+, PEDF+, and RPE65+ plus pigmented cytoplasm descriptor. It covers two differentiation process formats in independent claims: thick multilayer overgrowth (on MEF in one formulation) and embryoid body (EB), both converging on pigmented cell induction and isolation. The patent’s most enforceable elements are likely the endpoint identity constraints and the core workflow elements leading to brown cytoplasmic pigment and pigmented-cell isolation. Dependent claims add narrower constraints on: enzyme used for isolation (trypsin/collagenase/dispase), media additive absence (no exogenous FGF/LIF/PLASMANATE™), duration bands (6–8 weeks and 3–5 months), and specific administration settings (vitrectomy subretinal delivery; suspension/matrix/substrate). Competitor design-around is most plausible via process endpoint divergence (marker panel mismatch) or starting cell type change, with timing and enzyme/media/route constraints used to defeat dependent layers. FAQs Does the patent require Pax6 to be absent by a specific assay method? Are “brown pigment dispersed in cytoplasm” and bestrophin/CRALBP co-validated as an inseparable identity package? If a program uses iPSC-derived RPE instead of hES, does infringement risk persist under the same claim language? How do alternative routes of ocular delivery (intravitreal vs subretinal) map to dependent claim coverage? What manufacturing recordkeeping would most directly establish or refute the marker-panel endpoint in litigation? References (APA) No response. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	PLASMANATE	plasma protein fraction (human)	Injection	101140	October 02, 1958	8,268,303	2030-08-17
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965	8,268,303	2030-08-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 8,268,303

Summary for Patent: 8,268,303

US Patent 8,268,303: Critical Claims & U.S. Patent Landscape for hESC-Derived RPE (Pax6-/Bestrophin+/CRALBP+/PEDF+/RPE65+)

What is US 8,268,303 claiming for hES-to-RPE differentiation and cell identity?

Core claim scope: the “Pax6−/bestrophin+/CRALBP+/PEDF+/RPE65+” RPE endpoint

Two alternative process routes within the same concept

Pigmented-cell induction requirement

Isolation step as a narrower dependent constraint

Medium condition carve-outs as additional defense targets

Which U.S. uses are covered: retinal transplantation and Parkinson’s disease?

Administration claims (RPE cell administration with the same identity endpoint)

Retinitis pigmentosa and/or macular degeneration

Animal model evaluation of outcomes

Parkinson’s disease indication

What is the patent’s “most litigable” claim set: phenotype endpoint, timing, or route (MEF multilayer vs EB)?

Most central: the phenotype endpoint

Second focal: the differentiation workflow inputs

Timing bands matter mainly for dependents

How do the dependent claims create a layered design-around strategy?

Isolation-by-enzyme (trypsin/collagenase/dispase)

Medium additive exclusions (FGF, LIF, PLASMANATE™)

Feeder-free EB

Duration bands

What is the Orange Book status of US 8,268,303, and where would it likely show up?

Which companies are likely exposed to US 8,268,303 for hES-derived RPE and RPE cell therapy manufacturing?

What generic or biosimilar risk exists for this patent in U.S. cell therapy markets?

How strong is the patent estate around differentiation-to-RPE phenotype claims like this?

How does US 8,268,303 compare with adjacent RPE differentiation method patents (MEF multilayer vs EB)?

What patent-litigation events could impact enforceability or claim construction?

Key Takeaways

FAQs

References (APA)

Details for Patent 8,268,303

Make Better Decisions: Try a trial or see plans & pricing